Biocon shares rally nearly 6% after unit receives USFDA nod for cancer drug
Biocon's shares surged following USFDA approval for Jobevne, a biosimilar to Avastin, used in treating various cancers. This marks Biocon's seventh biosimilar approval in the U.S., strengthening its oncology portfolio. With bevacizumab sales reaching $2 billion in the U.S. in 2023, this (...)
Site référencé: The Economic Times
The Economic Times
Dolly Khanna adds over 5 lakh shares in this smallcap stock, raises stake to 2.18%
15/04/2025
Adani stocks rally up to 6% as Trump sarkar retreating from foreign bribery cases
15/04/2025
Bajaj Fin among 4 stocks that hit 52-wk highs on Tuesday
15/04/2025
Auto stocks skid up to 28% in a year ; muted Q4, FY26 outlook offers little hope. Here’s why
15/04/2025
Bajaj Housing Finance shares jump 5% as 1-year anchor lock-in ends today
15/04/2025
AIF Tracker : Samvitti Capital, Vivriti Asset Management & Northern Arc’s AIF Funds gave 12-15% returns in March 2025
15/04/2025
